Clinical Trial

Real-world Studies of CDK4/6 Inhibitors

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.
Trial Details
NCT Number NCT07407439
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Breast Cancer
Enrollment 245 participants
Start Date 2025-06-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-12